cetuximab, cisplatin

DRUG2 trials

Sponsors

Merck KGaA, Darmstadt, Germany, Institute of Oncology Ljubljana

Conditions

Breast NeoplasmHead and Neck Cancer

Phase 2

Cetuximab and Cisplatin in the Treatment of Triple Negative (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

CompletedNCT00463788

Merck KGaA, Darmstadt, GermanyBreast Neoplasm

Start: 2007-06-30End: 2011-02-28Updated: 2014-02-13

Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer

CompletedNCT00868491

Institute of Oncology LjubljanaHead and Neck Cancer

Start: 2008-03-31End: 2011-10-30Updated: 2024-10-18